Your browser is no longer supported. Please, upgrade your browser.
Settings
GRTS [NASD]
Gritstone Oncology, Inc.
Index- P/E- EPS (ttm)-2.87 Insider Own0.30% Shs Outstand37.75M Perf Week-7.44%
Market Cap554.74M Forward P/E- EPS next Y-2.35 Insider Trans- Shs Float37.75M Perf Month-21.56%
Income-105.90M PEG- EPS next Q-0.61 Inst Own77.60% Short Float7.53% Perf Quarter352.33%
Sales3.60M P/S154.09 EPS this Y-26.80% Inst Trans43.60% Short Ratio0.90 Perf Half Y320.12%
Book/sh1.91 P/B7.10 EPS next Y12.00% ROA-68.80% Target Price21.00 Perf Year60.21%
Cash/sh1.72 P/C7.87 EPS next 5Y- ROE-101.30% 52W Range2.54 - 35.20 Perf YTD244.42%
Dividend- P/FCF- EPS past 5Y- ROI-72.90% 52W High-61.45% Beta-
Dividend %- Quick Ratio3.40 Sales past 5Y- Gross Margin- 52W Low435.31% ATR2.52
Employees177 Current Ratio3.40 Sales Q/Q-10.00% Oper. Margin- RSI (14)46.59 Volatility9.80% 9.67%
OptionableYes Debt/Eq0.00 EPS Q/Q10.50% Profit Margin- Rel Volume0.15 Prev Close13.27
ShortableYes LT Debt/Eq0.00 Earnings- Payout- Avg Volume3.17M Price13.57
Recom2.00 SMA20-12.01% SMA5018.60% SMA200128.53% Volume486,375 Change2.26%
Jan-20-21Downgrade Robert W. Baird Outperform → Underperform $8
Jul-26-19Initiated Robert W. Baird Outperform $17
Mar-15-19Initiated Raymond James Outperform
Mar-07-19Initiated H.C. Wainwright Buy $17
Oct-23-18Initiated Goldman Neutral $18
Oct-23-18Initiated BTIG Research Buy $26
Feb-11-21 06:55AM  
Feb-01-21 04:21PM  
06:17AM  
06:00AM  
04:10AM  
Jan-27-21 08:19AM  
Jan-23-21 06:14AM  
Jan-21-21 08:16AM  
08:05AM  
Jan-20-21 07:33PM  
04:34PM  
04:13PM  
12:13PM  
09:25AM  
08:00AM  
Jan-19-21 03:27PM  
06:00AM  
Jan-11-21 08:00AM  
Dec-28-20 08:00AM  
Dec-23-20 08:33AM  
Dec-04-20 10:15AM  
Nov-05-20 09:01AM  
Nov-02-20 08:00AM  
Sep-21-20 09:27AM  
Sep-15-20 08:00AM  
Sep-08-20 08:00AM  
Aug-06-20 05:19PM  
Aug-05-20 10:25AM  
09:01AM  
Aug-03-20 12:31PM  
08:00AM  
Jul-22-20 02:28PM  
Jun-24-20 08:00AM  
Jun-14-20 08:59PM  
Jun-10-20 08:00AM  
Jun-04-20 08:00AM  
May-22-20 09:15AM  
May-10-20 10:14AM  
May-07-20 11:15AM  
09:01AM  
May-01-20 08:00AM  
Apr-06-20 08:00AM  
Mar-13-20 08:30AM  
Mar-11-20 10:25AM  
09:01AM  
Feb-25-20 04:00PM  
12:09PM  
Jan-08-20 04:00PM  
Jan-01-20 11:27AM  
Dec-16-19 07:36AM  
Dec-12-19 07:38AM  
05:05AM  
Dec-09-19 08:00AM  
Nov-26-19 08:00AM  
Nov-12-19 10:15AM  
09:01AM  
Nov-06-19 10:30AM  
Nov-05-19 08:05AM  
Oct-31-19 08:00AM  
Oct-07-19 08:00AM  
Sep-27-19 08:22AM  
Sep-26-19 08:00AM  
Sep-12-19 08:00AM  
Aug-14-19 03:40PM  
08:00AM  
Aug-12-19 09:01AM  
Jul-08-19 08:00AM  
Jun-05-19 08:00AM  
Jun-03-19 11:00AM  
May-30-19 08:00AM  
May-27-19 07:39AM  
May-13-19 09:01AM  
May-09-19 08:56PM  
Apr-25-19 11:42AM  
07:58AM  
Apr-24-19 08:53PM  
Apr-23-19 08:08AM  
Apr-22-19 04:28PM  
08:00AM  
Apr-04-19 08:00AM  
Apr-03-19 04:00PM  
10:02AM  
Apr-02-19 04:00PM  
Mar-28-19 04:00PM  
Mar-25-19 09:19AM  
Mar-21-19 04:00PM  
Mar-11-19 08:00AM  
Mar-05-19 04:00PM  
Feb-27-19 06:12PM  
Feb-20-19 04:00PM  
Jan-06-19 08:00AM  
Jan-03-19 06:16PM  
Dec-28-18 10:11AM  
Dec-20-18 04:00PM  
Dec-19-18 04:17PM  
Dec-17-18 11:00AM  
Dec-15-18 08:03AM  
Dec-13-18 05:18PM  
Dec-10-18 07:00AM  
Nov-26-18 02:03PM  
Gritstone Oncology, Inc., a clinical-stage biotechnology company, engages in developing tumor-specific cancer immunotherapies to fight various cancer types and infectious diseases. Its lead product candidate is GRANITE, which is in Phase I/II clinical trial for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate which is in Phase I/II clinical study for the treatment of common solid tumors, including metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and other mutation-positive tumors. Gritstone Oncology, Inc. has a strategic collaboration with bluebird bio, Inc. The company was founded in 2015 and is headquartered in Emeryville, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Rousseau RaphaelSee RemarksJan 20Option Exercise0.7610,0007,60010,000Jan 21 05:11 PM
Rousseau RaphaelSee RemarksJan 20Sale25.0710,000250,7050Jan 21 05:11 PM
Rousseau RaphaelSee RemarksJan 19Option Exercise0.7620,00015,20020,000Jan 21 05:11 PM
Rousseau RaphaelSee RemarksJan 19Sale17.5320,000350,5640Jan 21 05:11 PM
Yelensky RomanSee RemarksJan 19Sale22.1010,000221,029133,224Jan 21 05:06 PM
Woiwode ThomasDirectorDec 30Buy3.711,347,7095,000,0001,347,709Jan 04 06:02 PM
Jones ErinSee RemarksAug 17Option Exercise0.3510,0003,45020,000Aug 19 07:05 PM